Hereditary haemorrhagic telangiectasia

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase I/II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I/II

1 trial
  • Alnylam Pharmaceuticals Inc. Commercial
    RNA, (UM-SP-(2′-DEOXY-2′-FLUORO)A-SP-GM-AM-AM-(2′-DEOXY-2′-FLUORO)A-CM-UM-CM-AM-UM-AM-GM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)A-UM-UM-GM-CM-AM-SP-CM-SP-AM), COMPLEX WITH RNA (UM-SP-GM-SP-CM-AM-AM-UM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)U-(2′-DEOXY-2′-FLUORO)A-UM-GM-AM-GM-UM-UM-UM-CM-UM-AM) 3′-[[(2S,4R)-1-[29-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-14,14-BIS[[3-[[3-[[5-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]PROPYL]AMINO]-3-OXOPROPOXY]METHYL]-1,12,19,25-TETRAOXO-16-OXA-13,20,24-TRIAZANONACOS-1-YL]-4-HYDROXY-2-PYRROLIDINYL]METHYL HYDROGEN PHOSPHATE] (1:1)
    2025-522510-23-00 3 countries 2025 n=16
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Alnylam Pharmaceuticals Inc. Commercial 1 Phase I/II 0
New trials by year
2025
1
← All indication landscapes